MicroRNA-1224 Inhibits Tumor Metastasis in Intestinal-Type Gastric Cancer by Directly Targeting FAK

Jin Wang(Soochow University), Yunpeng Liu(Shenyang Institute of Automation), Ti Wen(Nankai University), Lingzi He(First Hospital of China Medical University), Huali Tang(Institute of Crop Sciences), Xiujuan Qu(First Hospital of China Medical University), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Xianghong Yang(China Medical University), Xiaofang Che(First Hospital of China Medical University), Libao Gong(First Hospital of China Medical University)
Frontiers in Oncology
April 4, 2019
10.3389/fonc.2019.00222
Cited by 37

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417